Nymox Pharma Updates On NX-1207 Phase 3 Trials

Nymox Pharma said that the patient recruitment and trial activities for pivotal US studies NX02-0017 and NX02-0018 are proceeding at over 60 well-known urology investigative sites throughout the US.

NX-1207 has been shown to improve the signs and symptoms of BPH, producing improvements which reached statistical significance compared to double-blinded placebo and study controls. A single administration of NX-1207 2.5mg has produced on average improvements in the standardised BPH symptom score (8-10 points) that were approximately double that reported for currently approved BPH drugs (3-5 points). Follow-up studies have shown clinical efficacy effects in men lasting up to 5 years after a single treatment.

In a recently published article entitled, NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia,’ written by Neal Shore, medical director of the Carolina Urologic Research Center, Myrtle Beach, SC, said: “Regarding existing oral drug therapies, the use of NX-1207 would obviate daily and lifelong compliance issues as well as the ongoing concerns of polypharmacy facing the elderly and the attendant risk for drug–drug interactions.

“In comparison to office-based MIST options, the transrectal injection approach afforded by NX-1207, both anesthetic/analgesic free as well as catheter free, will be quite compelling to most patients. If the ongoing Phase III trials can duplicate the success seen in earlier trials, for both efficacy and safety, then the administration of NX-1207 should be expected to significantly impact the current pattern of treatment options employed by urologists for their patients with BPH.”